Loading...

PE anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2
PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
  • XMG1.2
    PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
Compare all formats See PE spectral data
Cat # Size Price Save
505807 25 µg ¥8,580
505808 100 µg ¥20,700
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  2. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  3. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  4. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  5. Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed
  6. Jia JJ, et al. 2022. J Leukoc Biol. 112:157. PubMed
  7. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  8. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  9. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  10. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  11. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  12. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  13. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  14. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  15. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  16. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  17. Chan L, et al. 2022. Cells. 12: . PubMed
  18. Liu H, et al. 2023. Cell Death Differ. :. PubMed
  19. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  20. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  21. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  22. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  23. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  24. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  25. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  26. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  27. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  28. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  29. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  30. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  31. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  32. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  33. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  34. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  35. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  36. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  37. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  38. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  39. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  40. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  41. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  42. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  43. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  44. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  45. Chen Y, et al. 2020. Virol Sin. . PubMed
  46. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  47. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  48. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  49. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  50. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  51. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  52. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  53. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  54. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  55. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  56. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  57. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  58. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  59. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  60. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  61. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  62. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  63. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  64. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  65. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  66. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  67. Dong L, et al. 2021. Cancer Cell. . PubMed
  68. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  69. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  70. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  71. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  72. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  73. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  74. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  75. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  76. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  77. Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed
  78. Saito S, et al. 2020. Nutrients. 12:. PubMed
  79. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  80. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  81. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  82. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  83. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  84. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  85. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  86. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  87. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  88. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  89. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  90. Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed
  91. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  92. Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed
  93. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  94. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  95. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  96. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  97. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  98. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  99. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  100. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  101. An J, et al. 2022. iScience. 25:103570. PubMed
  102. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  103. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  104. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  105. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  106. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  107. Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed
  108. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  109. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  110. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  111. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  112. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  113. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  114. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  115. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  116. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  117. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  118. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  119. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  120. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  121. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
  122. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  123. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  124. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  125. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  126. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  127. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  128. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  129. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  130. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  131. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  132. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  133. Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed
  134. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  135. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  136. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  137. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  138. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  139. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  140. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  141. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  142. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  143. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  144. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  145. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  146. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  147. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  148. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  149. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  150. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  151. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  152. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  153. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  154. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  155. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  156. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  157. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  158. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  159. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  160. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  161. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  162. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  163. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  164. Zhang J, et al. 2018. Nature. 553:91. PubMed
  165. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  166. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  167. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  168. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  169. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  170. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  171. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  172. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  173. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  174. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  175. Miao W, et al. 2020. J Immunol. 1486:204. PubMed
  176. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  177. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  178. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  179. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  180. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  181. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  182. Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed
  183. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  184. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  185. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  186. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  187. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  188. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  189. Zhang X, et al. 2020. J Cancer. 11:648. PubMed
  190. Molgora M, et al. 2020. Cell. 182:886. PubMed
  191. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  192. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  193. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  194. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  195. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  196. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  197. Li H, et al. 2022. iScience. 25:104481. PubMed
  198. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  199. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  200. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  201. Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed
  202. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  203. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  204. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  205. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  206. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  207. Zheng Y, et al. 2022. Transl Res. :. PubMed
  208. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  209. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  210. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  211. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  212. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  213. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  214. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  215. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  216. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  217. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  218. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  219. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  220. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  221. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807)
AB_315402 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/11/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account